JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

  NCT03605849

  Conditions:   Attention Deficit Disorder;   Attention Deficit Hyperactivity Disorder
  Intervention:   Drug: Centanafadine SR
  Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
  Recruiting
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

  NCT03901482

  Conditions:   Migraine;   Migraine With Aura;   Migraine Without Aura
  Interventions:   Drug: Dihydroergotamine;   Drug: Placebos
  Sponsor:   Satsuma Pharmaceuticals, Inc.
  Recruiting
• Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects

  NCT03817684

  Condition:   Alzheimer's Disease
  Interventions:   Drug: BPN14770;   Drug: Placebo
  Sponsor:   Tetra Discovery Partners
  Recruiting
• Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep

  NCT03679884

  Condition:   Insomnia Disorder
  Interventions:   Drug: ACT-541468 10 mg;   Drug: ACT-541468 25 mg;   Drug: ACT-541468 50 mg;   Drug: Placebo
  Sponsor:   Idorsia Pharmaceuticals Ltd.
  Recruiting
• A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

  NCT03561090

  Condition:   Gastroesophageal Reflux Disease (GERD)
  Interventions:   Drug: IW-3718;   Drug: placebo
  Sponsor:   Ironwood Pharmaceuticals, Inc.
  Recruiting
• Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder

  NCT03545191

  Condition:   Insomnia Disorder
  Interventions:   Drug: ACT-541468;   Other: Placebo
  Sponsor:   Idorsia Pharmaceuticals Ltd.
  Recruiting
• A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

  NCT03504917

  Condition:   Autism Spectrum Disorder
  Interventions:   Drug: Balovaptan;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

  NCT03443973

  Condition:   Alzheimer's Disease
  Interventions:   Drug: Gantenerumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• ePneumonia: Development of an Electronic Clinical Decision Support System for Community-Onset Pneumonia

  NCT03358342

  Condition:   Pneumonia
  Intervention:   Other: ePneumonia CDS
  Sponsor:   Intermountain Health Care, Inc.
  Recruiting
• Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

  NCT02993406

  Conditions:   Cardiovascular Diseases;   Statin Adverse Reaction
  Interventions:   Drug: Bempedoic acid 180 mg tablet;   Drug: Matching placebo tablet
  Sponsors:   Esperion Therapeutics;   The Cleveland Clinic
  Recruiting
• Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

  NCT04084769

  Condition:   Meningococcal Infection (Healthy Volunteers)
  Interventions:   Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine;   Biological: Meningococcal Group B Vaccine (Trumenba®);   Biological: Meningococcal group B Vaccine (Bexsero®)
  Sponsor:   Sanofi Pasteur, a Sanofi Company
  Recruiting
• A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

  NCT03607422

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
  Sponsor:   AbbVie
  Recruiting